Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Donald R VanDevanterMichael W Konstan

Abstract

Cystic fibrosis (CF) pulmonary exacerbations can be serious respiratory events and reduction in exacerbation rate or risk are important efficacy endpoints for CF therapeutic trials. Variability in exacerbation diagnoses and treatment have led drug developers to employ "objective" exacerbation definitions combining antimicrobial treatment (AT) and the presence of ≥4 of 12 respiratory criteria (first published by Fuchs et al. [NEJM 1994;331(10):637-42]). Assumptions underlying this approach have yet to be formally evaluated. Respiratory events (RE) observed during a 48-week trial of ataluren (NCT02139306), a read-through agent for premature nonsense codons, were compared across six exacerbation definitions: any AT, intravenous AT (IVAT), ≥4 Fuchs criteria present, AT plus ≥4 Fuchs criteria, IVAT plus ≥4 Fuchs criteria, and investigator assessment. Fuchs definitions were evaluated by assessing missingness of individual criteria and associations between criteria presence and clinician exacerbation assessment. Among 751 RE, more than one third had ≥4 Fuchs criteria present but were not assessed as exacerbations by investigators. Data for ≥1 and for 4 Fuchs criteria, respectively, were missing for ~ 90% and >30% of RE. Only 6/12 Fuch...Continue Reading

References

Feb 24, 2001·American Journal of Epidemiology·T G LiouB C Marshall
Oct 31, 2002·American Journal of Respiratory and Critical Care Medicine·Nicole Mayer-HamblettMoira L Aitken
Feb 28, 2003·Lancet·Felix Ratjen, Gerd Döring
Mar 28, 2007·Thorax·Christopher H Goss, Jane L Burns
Sep 5, 2009·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Clinical Practice Guidelines for Pulmonary Therapies Committee
Sep 22, 2009·Pediatric Pulmonology·Lijing OuyangMichael S Schechter
Apr 6, 2011·Pediatric Pulmonology·Nathan C KraynackJohn T McBride
Nov 4, 2011·The New England Journal of Medicine·Bonnie W RamseyUNKNOWN VX08-770-102 Study Group
Aug 14, 2012·Pediatric Pulmonology·Jeffrey S WagenerUNKNOWN Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Jan 1, 2013·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Donald R VanDevanterUNKNOWN Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
May 20, 2014·The Lancet. Respiratory Medicine·Eitan KeremUNKNOWN Cystic Fibrosis Ataluren Study Group
Jan 1, 2012·Clinical Investigation·Donald R VanDevanter, Michael W Konstan
Jun 14, 2017·American Journal of Respiratory and Critical Care Medicine·Noah LechtzinUNKNOWN eICE Study Team

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02139306

Software Mentioned

MedCalc
R Statistical Programming Language

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Related Papers

Medicinski Arhiv
R Alajbegović
Bulletin des sociétés d'ophtalmologie de France
L CALMETTES
Ophthalmology
Kristina May, Matthew Edwards
© 2021 Meta ULC. All rights reserved